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Nanostructured lipid carriers (NLCs) loaded with palmitoylethanolamide (PEA) were
formulated with the aim to enhance ocular bioavailability of PEA, particularly to the
back of the eye. Technological characterization (e.g., size, charge) of NLC loaded with
PEA formulation (PEA-NLC) was performed, and NLC morphology was characterized
by electron microscopy. Ocular pharmacokinetic study, after topical administration of the
formulation, was carried out in rabbit eye. Ultra-high performance liquid chromatography
tandem mass spectrometry analysis was carried out to detect PEA levels in ocular
tissues. Finally, the ocular tolerability of PEA-NLC formulation was assessed in rabbit
eye. The novel formulation significantly increased PEA levels in ocular tissues compared
to PEA suspension. Vitreous and retinal levels of PEA were significantly higher in
the group treated with PEA-NLC formulation versus PEA suspension (PEA-NLC Cmax
5919 ± 541 pmol/g and 315 ± 70 pmol/g in vitreous and retina, respectively). The PEA-
NLC formulation was characterized by high stability and robust ocular bioavailability.
Therefore, this innovative formulation may be useful in clinical practice to manage retinal
diseases.
Keywords: palmitoylethanolamide, nanostructured lipid carriers, ocular drug delivery, retinal diseases, diabetic
retinopathy
INTRODUCTION
Topical application of eye drops is the most common route of administration of ophthalmic drugs.
Ophthalmic drug delivery, especially to the posterior eye segment, is one of the most challenging
endeavors facing ocular pharmacologists. Ocular bioavailability of drugs which are administered
by conventional solutions and suspensions is affected by a series of drug removal pre-corneal
mechanisms which drastically reduce the amount of trans-corneal drug absorption (Puglia et al.,
2015). Other unfavorable characteristics affecting the ocular delivery of drugs through the topical
route are represented by the physiological barriers that limit significantly the drug absorption
in the back of the eye (i.e., blood–aqueous barrier and the blood–retinal barrier) (Del Amo and
Urtti, 2008; Bucolo et al., 2012). Therefore, frequent instillation of eye drops is necessary to
obtain the expected therapeutic effect, even if discomfort and a decrease in patient compliance,
especially in chronic therapy, are often observed (Battaglia et al., 2016). Delivery of drugs to the
posterior eye is challenging, and there is an increasing need for therapeutic management of rapidly
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progressing retinal eye diseases, such as diabetic retinopathy, age-
related macular degeneration, and optic neuropathy. Recently,
an extraordinary effort has been made to develop new drug
delivery systems, that prolong the corneal residence time
to ameliorate the ocular bioavailability of ophthalmic drugs
(Pignatello and Puglisi, 2011; Duan et al., 2015; Yu et al.,
2015; Sanchez-Lopez et al., 2017). Nanostructured lipid carriers
(NLC) are interesting nanosized particles belonging to the
family of lipid nanoparticles (NPs), and NLC represent second
generation NPs (Figure 1). They show important features
advantageous for ocular application, such as controlled drug
release, high drug loading, good bioavailability and excellent
tolerability (Araújo et al., 2011; Puglia et al., 2015). Many
scientific evidences demonstrate the NLC ability to improve
the interaction with the ocular mucosa, prolonging the corneal
residence time of the loaded drug, thus producing, on the
one hand, an increase of the ocular bioavailability and, on the
other hand, a reduction of the local and systemic side effects.
Therefore, NLC are currently studied as delivery systems for
the treatment of most important ocular disorders, from the
common ocular inflammation or infection to important diseases
affecting the posterior eye segment (Luo et al., 2011; Balguri
et al., 2016; Tronino et al., 2016). Palmitoylethanolamide (PEA)
is an endogenous congener of the endocannabinoid anandamide
(AEA) with a potent anti-inflammatory activity, which can be
exploited in different pathological conditions and in a variety of
biological systems including retina (Matias et al., 2006; Petrosino
et al., 2010). There are several reports highlighting that PEA
can exert beneficial effects in several retinal diseases such as
diabetic retinopathy, glaucoma, etc. A recent paper showed
that PEA attenuated the degree of retinal inflammation while
preserving the blood–retinal barrier in diabetic rats (Paterniti
et al., 2015). Moreover, systemic PEA treatment was found to
be effective in ameliorating visual field of glaucoma patients
while decreasing intraocular pressure (IOP), which is the main
risk factor of glaucoma (Gagliano et al., 2011; Costagliola et al.,
2014). Furthermore, topical ocular PEA treatment was recently
found to be effective in attenuate ocular surface inflammation in
humans (Di Zazzo et al., 2017). The pharmacological properties
of PEA include effects upon mast cells, CB2 -like cannabinoid
receptors, ATP-sensitive K+-channels, TRP channels and NF-κB.
However, the most robust evidence is related to the activity of
PEA on the nuclear receptor peroxisome proliferator-activated
receptor α (PPARα) (Lo Verme et al., 2005; LoVerme et al.,
2006). Despite the potential pharmacological applications of
PEA, its clinical application is strongly compromised by an
unfavorable pharmacokinetic profile. PEA is a poorly water-
soluble molecule (Figure 1), this physical chemical property
limits the development of PEA eye drops, therefore, the
aim of the present study was to set up a new ophthalmic
formulation using innovative nanoparticles in order to enhance
ocular bioavailability of PEA. Technological characterization of
the novel formulation (PEA-NLC) was performed, and NLC
morphology was assessed by electron microscopy. Finally, an
in vivo study was carried out to assess formulation tolerability
and pharmacokinetic profile of PEA after ocular administration
in rabbit eye.
MATERIALS AND METHODS
Materials
Compritol R© 888 ATO (COMP), a mixture of mono-, di-, and
triglycerides of behenic acid, was obtained from Gattefossè
(Milan, Italy); Miglyol R© 812 (MIG), a mixture of caprylic/capric
triglycerides, was obtained from Eigenmann & Veronelli S.p.A.
(Milan, Italy) and Lutrol R© F68 was provided by BASF Chem-
Trade GmbH (Burgbernheim, Germany). Micronized PEA was
a kind gift from Epitech Group (Milan, Italy). All the other
chemicals and reagents were of the highest purity grade
commercially available and were used as received.
Lipid Nanoparticles Preparation
Palmitoylethanolamide-loaded NLC were prepared by high
shear homogenization (HSH) method, following the procedure
previously reported (Giannavola et al., 2003). Briefly, MIG
(0.375 g) and PEA (0.260 g) were added to 1.5 g of molten COMP
(80◦C) and the mixture was stirred to obtain a dispersion.
The molten lipid phase was dispersed in 25 mL of hot (80◦C)
saline containing Lutrol R© F68 (0.4% w/v), by using a high shear
homogenizer (UltraTurrax T25; IKA-Werke GmbH & Company
KG, Germany) at 13,500 rpm for 10 min. The hot dispersion
was then cooled by dilution in 25 mL of additional water at
4◦C. The resulting dispersion was then subjected to high-speed
homogenization (8000 rpm) for 5 min. Unloaded NLC were
prepared by the same procedure without adding PEA.
Particle Size and Zeta Potential
Measurement
NLC mean hydrodynamic diameter (mhd) and Zeta potential
were determined using a Zetamaster instrument (Malvern
Instrument, Ltd., Sparing Lane South, Worcs, United Kingdom),
equipped with a solid state laser having a nominal power of
4.5 mW with a maximum output of 5 mW at 670 nm. All the
measurements were carried out using a 90◦ scattering angle
at 20 ± 0.2◦C. Before measurements of particle size and Zeta
potential, 10 µL of each sample suspension was diluted in 2 mL
FIGURE 1 | Structure of PEA (palmitoylethanolamide) and lipid nanoparticles
(NPs). 1st generation of lipid NPs (SLN, solid lipid nanoparticles) and 2nd
generation of lipid NPs (NLC, nanostructured lipid carriers).
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of ultrapure water, previously filtered through a 0.2 µm Acrodisc
LC 13 PVDF filter (Pall-Gelman Laboratory, Ann Harbor, MI,
United States).
Morphological Studies
NLC morphology was evaluated by means of transmission
electron microscopy (TEM) (Philips EM 400T microscope,
Eindhoven, Netherlands) and field emission scanning electron
microscopy (FE-SEM) (LEO 1525 equipped with a GEMINI
column, ZEISS, Germany). TEM samples were prepared by
deposition of a drop of diluted (100 folds) NLC suspension
on the surface of a 200 mesh Formvar R©-coated copper grid
(TAAB Laboratories Equipment, Ltd., Aldermaston, England)
and letting drop to evaporate at room temperature overnight.
To investigate particle internal morphology by FE-SEM, the
suspension was lyophilized, then particles were broken up in dry
ice and, after CO2 complete vaporization, re-dispersed in water.
Specimens were prepared by deposition of diluted (100 folds)
NLC suspension onto an aluminum specimen stub covered with
a double sided adhesive carbon disk. After water vaporization at
room temperature, samples were sputter coated with chromium
prior to imaging (Quorum Q150T ES East Grinstead, West
Sussex, United Kingdom). Coating was done at 120 mA for 30 s.
Ocular Pharmacokinetics
Experimental protocol was approved by the Institutional Animal
Care and Use Committee of the University of Catania (Catania,
Italy) and complied with the statements of Association for
Research in Vision and Ophthalmology (ARVO) for use of
animals in ophthalmic and visual research. New Zealand rabbits
(weight 2.0–2.5 kg) were purchased from Envigo (San Piero
al Natisone, Udine, Italy). Rabbits were housed in standard
conditions, with free access to food and water, in a light-
controlled room at controlled range of temperature (22 ± 1◦C)
and humidity (10–30%). Rabbits were sacrificed by intravenous
administration of 0.3 ml/kg of Tanax R© (Intervet, Milan, Italy),
after sedation with an intramuscular administration of 10 mg/kg
of Zoletil R© (Virbac, Milan, Italy).
Rabbits were randomly assigned to two experimental groups
(n = 8 per group), receiving single ocular topical administration
(30 µL) of PEA-NLC and PEA suspension, respectively.
Palmitoylethanolamide concentration was 0.05% w/v,
corresponding to [PEA] = 17.4 mM, both in the NLC formulation
and suspension. A different set of animals (n = 6) was used to
determine PEA content in tissues of control animals, that
received topically 30 µL of unloaded NLC (n = 3) and pH 7.4
PBS (n = 3). Animals were sacrificed at 30, 60, 120, and 180 min
after ocular topical administration of PEA-NLC and PEA
suspension. Eyes were enucleated and ocular tissues (lens, humor
vitreous, and retina) were then collected. Tissue samples were
stored at −80◦C till quantitative analysis of PEA. The following
pharmacokinetics parameters were determined: peak eye tissue
concentration (Cmax), time of peak of eye tissue concentration
(Tmax), area under the curve (AUC0−180) of eye tissue building
the curve (concentration of PEA [PEA] vs. time curve from 0
to 180 min). PEA concentration values in the tissues of treated
animals were normalized to PEA content in tissue of control
animals.
Ocular Tolerability
The potential ocular irritancy and/or damaging effects of
unloaded NLC and PEA-NLC formulations were evaluated
according to a modified Draize’s test in a separate set of animals
(4 animals/group) (Leonardi et al., 2014). Analysis was carried
out using a slit lamp (mod. 4179 T Sbisà, Florence, Italy).
Formulations (30 µL) were topically administered in the right
eye every 30 min for 6 h (12 treatments). Congestion, swelling,
and discharge of the conjunctiva were graded on a scale from
0 to 3 (0 = normal; 1, 2 and 3 = discrete, moderate and intense
dilatation of conjunctival vessels, respectively), 0 to 4 (0 = normal;
1, 2, 3 and 4 = discrete, moderate, intense, intense + lid closure
conjunctival swelling, respectively), and 0 to 3 (0 = normal; 1, 2
and 3 = discrete, moderate and intense discharge, respectively).
Iris hyperemia was graded on a scale from 0 to 4 (0 = normal,
1 = discrete dilatation of iris vessels; 2 = moderate dilatation of
iris vessels; 3 = intense iridal hyperemia with flare in the anterior
chamber; 4 = intense iridal hyperemia with flare in the anterior
chamber and presence of fibrinous exudates). Corneal opacity
was graded on a scale from 0 to 4 (0 = normal, 1 = some spots
of opacity; 2 = diffuse cortical opacity; 3 = cortical and nuclear
opacity; 4 = intense opacity plus posterior subcapsular opacity).
Formulations (30 µL) were topically administered in the right eye
every 30 min for 6 h (12 treatments). At the end of the treatment,
two observations at 10 min and 6 h were carried out in order
to evaluate the ocular tissues. Observations were made by two
independent observers in a masked way. Methylene blue staining
was used in order to evaluate the corneal integrity, which allows
an accurate determination of the extent of epithelial damage
because of its poor diffusion through the stromal layer of the
cornea.
Ultra-High Performance Liquid
Chromatography Tandem Mass
Spectrometry (UHPLC-MS/MS)
Vitreous humor samples were filtered by 0.45 µM Phenex
PTFE filters (Phenomenex, Castel Maggiore, BO, Italy), diluted
1:50 (v:v) with water (LCMS grade, Sigma Aldrich, Milan,
Italy) and then directly analyzed by UHPLC-MS/MS. Lens and
retina samples were brought to a temperature of −55◦C and
lyophilized overnight. Tissues were weighted, carefully crushed
in an agate mortar and extracted in order to remove sample
matrix interfering compounds. Extractions were performed
by MetaboPrep-LC extraction kit (Theoreo, Montecorvino
Pugliano, SA, Italy) according to the manufacturer’s instructions.
Resulting solutions were analyzed as described below. The
filtration and extraction methods were validated in control
experiments and by spiking the tissues with a known amount
of PEA before and after extraction. In all cases no interfering
peaks deriving from the samples were detected. The recovery
was in the range 97–115%. UHPLC-MS/MS analysis was carried
out with a Shimadzu Nexera (Shimadzu, Milan, Italy) UHPLC
consisting of two LC 30 AD pumps, a SIL 30AC auto-sampler, a
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CTO 20AC column oven, a CBM 20 A controller, and the system
was coupled online to a triple quadrupole LCMS 8050 (Shimadzu,
Kyoto, Japan) by a ESI source.
The separation was performed on a Ascentis Express R© HILIC
column 150 × 2.1 µm, 2.7 mm (Supelco, Bellefonte, PA,
United States) at a flow rate of 0.3 mL/min, employing as mobile
phase (A) water 0.05 M HCOONH4 and (B) ACN, with the
following gradient starting 0 min, 95% B, 0.01–3 min, 85% B,
3–6 min 85–40% B, isocratic for 30 s. Returning to 95% in 6 min.
2 microliters were injected. All additives and mobile phases were
LCMS grade and purchased from Sigma Aldrich (Milan, Italy).
The ESI was operated in positive ionization. MS/MS analysis was
conducted in multiple reaction monitoring (MRM), employing
as transitions: 300,4-62.2 (quantifier ion), 300,4-57.2 (qualifier
ion). Q1 pre bias −16.0, −16.0 V, collision energy: −16.0,
30.0, Q3 pre bias −26.0 −24.0 V. Dwell time 25 ms. Interface
temperature 300◦C, Desolvation line temperature 250◦C, Heat
Block temperature 400◦C, nebulizing gas, drying and heating gas:
3,10,10 L/min. All analyses were run in triplicate. Linearity of the
method was assessed in the range of 0.01–250 ppb values were
considered satisfactory (R2 = 0.9997). The low limit of detection
(LOD) that was defined as the analyte concentration providing a
signal-to-noise ratio of three, and it is considered the minimum
concentration of analyte that could be confidently measured by
the method (0.1 ppb).
Statistical Analysis
GraphPad Prism (version 5.0; GraphPad Software, San Diego,
CA, United States) was used for statistical analysis and graphical
representation. All data are expressed as mean ± SD unless
indicated otherwise. The results were analyzed using one-way
ANOVA followed by Tukey–Kramer multiple comparisons
test; Mann–Whiteny U-test was used for ordinal data. Data
were considered statistically significant using as cut-off
p-values< 0.05.
RESULTS
Nanoparticles: Characterization and
Electron Microscopy
NLC loaded with PEA (PEA-NLC), prepared by HSH method,
showed a mhd around 200 nm (208.6 ± 10.2 nm) with a
polydispersity index (PDI) of 0.18. Unloaded NLC showed
a lower mhd (171.3 ± 11.8) but a larger PDI (0.26). Both
suspensions had a negative Zeta-potential higher than |20|
mV, which should guarantee adequate suspension stability
(Muller et al., 2002). Steric hindrance, due to presence of
Poloxamer (Lutrol R© F68) on particle surface, might further
contribute to the colloid stability. NLC suspensions had a pH
of 7.64, compatible with ocular application, while osmolarity
(242 mOsm/kg) had to be adjusted with the addition of
174 mg of NaCl to achieve isotonicity (300 mOsm/kg).
Electron microscopy showed a particle size compatible with
the one estimated by photon correlation spectroscopy data
(Figure 2). The examination of particle internal structure at
high magnification (140.000X) evidenced the presence of low-
electrondense compartments within the matrix (Figure 2). These
low-electrondense compartments had the tendency to merge
together during sample heating by the microscope electron beam.
Figure 3 shows one fractured particle where it is possible to
observe oil nano-compartments (red arrows).
In Vivo Studies
The pharmacokinetic profile of a single 30 µL topical
administration of 0.05% PEA encapsulated in lipid NPs
(PEA-NLC) was compared to the same dose of PEA aqueous
suspension (PEA suspension) [0.05% w/v in phosphate buffered
saline (PBS); pH 7.4]. PEA had a Cmax in the lens about ninefold
higher when administered as lipid nanoparticles with respect to
the suspension; and AUC0−180 of PEA-NLC was about fivefold
greater (Figure 4A and Table 1) than AUC0−180 PEA-suspension.
In fact, after absorption in the anterior segment of the eye, PEA,
formulated as aqueous suspension, reached the vitreous, bearing
a Cmax = 138± 30 pmol/g, 180 min after the administration of the
PEA suspension (Figure 4B and Table 1). Furthermore, the Cmax
of PEA in rabbit vitreous, 180 min after topical administration of
PEA-NLC was about 43 fold higher (p< 0.01) than Cmax reached
after administration of PEA-suspension (Figure 4B and Table 1).
Worthy of note, PEA, administered as aqueous suspension, did
FIGURE 2 | Transmission electron microscopy (TEM) photographs of
PEA-NLC.
FIGURE 3 | Field emission-scanning electron microscopy photographs of a
fractured particle (PEA-NLC). Insert: enlargement of the fractured particle. Red
arrows indicate the nano-compartments.
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FIGURE 4 | Levels of PEA vs. time curves in lens (A), vitreous (B), and retina
(C) after treatment with PEA formulations. ∗p < 0.05. PEA-NLC vs.
PEA-suspension.
not reach detectable levels in the retina (Figure 4C and Table 1).
On the contrary, PEA encapsulated in NPs (PEA-NLC) reached
detectable levels in rabbit retina (Cmax = 315 ± 70 pmol/g)
(Figure 4C and Table 1). Ocular tolerability of blank NLC
and PEA-NLC was assessed in rabbit eye. Both formulations,
unloaded NLC and PEA-NLC, were well-tolerated and the score
for each parameter was zero at all time of observations.
DISCUSSION
Pharmacokinetics data showed that a new PEA ophthalmic
formulation (PEA-NLC) was able to deliver the molecule to the
back of the eye. The mechanism by which PEA is locally delivered
to the posterior segment from the pre-corneal area is likely
to be attributed to several factors depending on NLC peculiar
structure and morphology. The innovative NLC formulation
was characterized by high stability, vitreo-retinal bioavailability
and ocular tolerability. As previously reported (Tronino et al.,
2016), the presence of low-electrondense spherical objects and
their coalescence can be ascribed to the occurrence of MIG
oily nano-compartments dispersed in the COMP solid matrix,
as previously hypothesized (Muller et al., 2002). In fact, when
nanoparticles are prepared with a mixture of solid and liquid
lipids (e.g., oils), peculiar internal structures may be generated
(Muller et al., 2002). These kinds of particles have been called
NLC, and NLC can be differentiated as amorphous, imperfect,
and multiple types, on the basis of internal structure features.
The occurrence of one or another structure generally depends
on the physicochemical properties and the relative amount of
liquid excipient/s employed in the formulation. In the multiple
type NLC, the relative high oil content and the reduced
miscibility during particle solidification cause the separation
of the oil, leading to formation nano-compartments within
the solid matrix. The presence of these structures within the
particle matrix has been visualized by TEM and confirmed by
FE-SEM analysis (Figures 2, 3). NLC-formulation was further
characterized by small particle dimension (208.6± 10.2 nm) with
homogenous distribution of particle dimension (PDI = 0.18).
Furthermore, both unloaded and loaded NLC showed a high
stability to particle coalescence, bearing a negative Zeta-potential
higher than |20| mV. Ocular pharmacokinetic of PEA loaded
NLC (PEA-NLC) was compared to administration of aqueous
suspension of PEA (PEA-suspension); the concentration of
PEA was 0.05% in both ophthalmic formulations. Overall,
our data shows that NLC significantly increased PEA ocular
bioavailability in comparison to PEA delivered as aqueous
suspension even in the posterior segment of the eye. Ocular
TABLE 1 | Normalized pharmacokinetic parameters of topical ocular administration of PEA-NLC and PEA-suspension.
Pharmacokinetics parameters
PEA-NLC PEA-suspension
AUC (pmol·min/g) tmax (min) Cmax (pmol/g) AUC (pmol·min/g) tmax (min) Cmax (pmol/g) Basal [PEA] (pmol/g)
Lens ∗139639 ± 1532 30 2586 ± 485 27854 ± 2109 30 286 ± 135 409.6 ± 50.2
Vitreous ∗194673 ± 5957 180 5919 ± 541 5940 ± 567 180 138 ± 30 58.0 ± 4.7
Retina 22659 ± 786 180 315 ± 70 – – – 246.6 ± 28.8
∗p < 0.01 vs. PEA-suspension.
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tissues distribution of PEA suspension indicated that after
instillation the drug followed a canonical direction from the
anterior to the posterior segment of the eye; accounting mainly
for a trans-corneal drug absorption mechanism (Bucolo et al.,
2012) and, at least in part, to trans-scleral absorption, given
PEA-suspension Cmax = 138 ± 30 pmol/g in rabbit vitreous,
180′ after administration (Figure 4B and Table 1). PEA-
NLC topical administration provided high retinal PEA levels
(Cmax 315 pmol/g), this amount is comparable to PEA levels
(200 pmol) that were found to be pharmacological effective in
two in vitro inflammation paradigms (Avagliano et al., 2016;
Sarnelli et al., 2016). Additionally, we found that PEA basal
levels (246.6 pmol/g) were superimposable to physiological PEA
concentration found in healthy human retina (Chen et al., 2005).
In terms of safety, our results are in accordance with recent
published studies on SLN and poloxamers from other groups.
For instance, Gökçe et al. (2009) demonstrated that poloxamer
188, used to formulate SLN, was safe on the ocular tissues in
a weight concentration ranging from 0.1 to 0.4%. Furthermore,
safety of surfactant Lutrol R© F68, used in SLN, was proven by
Araújo et al. (2011) that showed a full biocompatibility with
the ocular tissues. Recently, it has been demonstrated that SLN
stabilized by Poloxamer 188 are safe in rabbit eye (Leonardi et al.,
2014).
In general, the mechanism by which drugs may be
delivered to the posterior segment from the pre-corneal area is
unknown. The evidence seems to indicate a non-corneal route,
possibly involving conjunctival/scleral absorption followed by
distribution to choroid, vitreous and retina, even though classical
corneal absorption cannot be ruled out. Overall our data indicate
that NLC could be able both to enhance PEA permeation through
the conjunctival/scleral route and to facilitate the drug crossing
through the corneal barrier. The latter mechanism is object of
scientific debate since it seems that most NPs greater than 50 nm
are readily immobilized by ocular mucus due to interactions with
the mucin mesh (Lai et al., 2009; Schopf et al., 2015). Indeed,
the ocular residence time of such trapped NPs should be related
to the rapid turnover rate of the ocular mucus, typically in the
order of seconds to minutes (Bala et al., 2004). We hypothesize
that due to the characteristics of lipid shell, surrounded by the
surfactant layer, our NLC by-pass tear mucin barrier and easily
reach corneal glycocalyx layer. Therefore, penetrating the mucus
layer, PEA-NLC guaranteed enhanced PEA delivery to ocular
tissues, improving drug pharmacokinetics profile. In fact, it is
well-known that mucin fibers are densely coated with negative
charges and therefore they bind with high avidity positively
charged particles by means of polyvalent adhesive interactions,
including hydrophobic and electrostatic forces (Schopf et al.,
2015). This feature represents a particularly challenging problem
for positive charged NPs, designed to deliver drugs and genes
(Ponchel et al., 1997).
Conversely, on the basis of previous reports (Bhat et al., 1996;
Gökçe et al., 2009), free hydrophobic drug (PEA-suspension)
diffusion would be dramatically affected by mucin layer, due to
interaction with hydrophobic domain of mucus. Even though,
after saturation of mucin binding sites, mucin fibers can act as
merely inert fillers, as it was found in a model of mucus layer
permeation (Bhat et al., 1995). Meaning that, after saturation
of mucus layer binding sites, NLC and free drug would exhibit
steady-state fluxes similar to those of buffer solution. Therefore,
this effect of mucin barrier on steady-state fluxes of drug and
particles explain why free PEA can cross the cornea, although to
a less extent compared to PEA-NLC.
Despite the recent scientific literature reports many examples
of interesting SLN (ancestors of NLC) application in ocular
topical administration (Kakkar et al., 2015; Okur and Gökçe,
2017; Sanchez-Lopez et al., 2017), the results generated from
these studies are very far to our data obtained with NLC
(Figure 1). We demonstrated that the topical administration of
PEA encapsulated in NLC resulted in a 40 and 100% increase of
PEA levels in vitreous and retina, respectively, when compared
with PEA suspension application.
CONCLUSION
Taken together, our data indicate that the new ophthalmic
formulation containing palmitoylethanolamide (PEA-NLC) has
good ocular distribution, delivering high levels of drug in the back
of the eye, after topical ocular administration. Therefore, this
formulation may be useful in clinical practice to manage retinal
diseases, indeed, clinical studies to evaluate this possibility may
be warranted.
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